Clinical observatiaon of lobaplatin plus etoposide in the treatment of esophageal small cell of carcinoma / 中国基层医药

ABSTRACT

Objective To observe curative effect of lobaplatin plus etoposide,the new antitumor platinum drugs,on the untreated esophageal small cell of carcinoma.Methods Sixteen patients with esophageal small cell of carcinoma were treated using the lobaplatin/vp16 regimen.Results The complete response (CR) rates were 31.3%,partial response (PR)rates were 37.5%,stable disease (SD)rates were 25%,progressive disease (PD) rates were 6.25%,overall response rate (ORR)68.8%.Languor was the most common symptom in the grade -ⅠtoⅣ adverse reactions.All patients had symptoms of languor.Other related symptoms included the anaemia (41.7%), leukocytopenia (39.7%),thrombocytopenia (20.9%),anorexia,vomiting,nausea (29.3%)and increase of ALT and AST (14.5%).The toxic effect was not serious damage.Conclusion Lobaplatin is a new and safe antitumor platinum drug with a promising clinical effect,has a good tolerance in patients,and it can try to be used in the patients who have esophageal small cell of carcinoma.